CXCL10

[Cancer Discovery] The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.

[Nature Cancer] Scientists reported a Phase I–cleared orally bioavailable MTKI, ESK981, with a novel autophagy inhibitory property that decreased tumor growth in diverse preclinical models of castration-resistant prostate cancer.

[Journal of Experimental Medicine] The authors discovered that selective recruitment and activation of systemic CD8+ T cells into DNA mismatch repair colorectal cancers strictly depend on overexpression of CCL5 and CXCL10 due to endogenous activation of cGAS/STING and type I IFN signaling by damaged DNA.

[Nature Medicine] Researchers showed that engineering of a medium-length CAR spacer enhances the therapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orthotopic xenograft medulloblastoma model.

[Scientific Reports] Investigators determined the effect of cell type-specific deletion of protease-activated receptor 1 (PAR1) in cardiac myocytes and cardiac fibroblasts on Coxsackievirus B3-induced myocarditis.

[npj Precision Oncology] RNAseq was performed on EGFR mutant cell lines treated in vitro with osimertinib and on tumor biopsies of eight EGFR mutant lung cancer patients before and after 2 weeks of tyrosine kinase inhibitorstreatment.